Business Context and Reporting Period
This Form 8-K was filed by Nutex Health Inc. on July 25, 2024, reporting events occurring on July 24, 2024. The filing addresses the Company's compliance status with The Nasdaq Stock Market LLC regarding its common stock listing.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and stock listing status.
Material Changes
The primary material event is the Company regaining compliance with Nasdaq Listing Rule 5550(a)(2). Following a 1:10 reverse stock split effective July 3, 2024, the closing bid price of the Company's common stock traded above $1.00 per share from July 3, 2024, through July 23, 2024. This satisfied the requirements set forth in the Hearing Panel's June 14, 2024 decision.
Guidance, Outlook, and Risks
The Nasdaq Hearing Panel determined to continue the listing of the Company's common stock on The Nasdaq Stock Market and closed the matter regarding the previous non-compliance. No forward-looking guidance, management commentary on operations, or new risk factors were disclosed in this specific report.
Investor Verification Checklist
- Verify the continued listing status of Nutex Health Inc. (NUTX) on The Nasdaq Stock Market.
- Confirm the impact of the 1:10 reverse stock split executed on July 3, 2024, on share count and price.
- Review the June 18, 2024 Form 8-K for details on the prior non-compliance notice and the Hearing Panel's initial decision.
- Monitor future stock price performance to ensure sustained compliance with the $1.00 minimum bid price requirement.